Latest Commercialisation News

INOVIQ Limited has completed a $9.5 million placement to institutional investors and launched a $2 million Share Purchase Plan for existing shareholders, aiming to bolster its cancer diagnostics and therapeutics pipeline.

Adveritas Limited has reported a record annualised recurring revenue of $12.2 million for the September 2025 quarter, driven by strong affiliate momentum and initial commercialisation of its Meta integration. The company is advancing its US expansion with a robust trial pipeline and expects significant contract conversions in the coming quarter.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Jade Gas Holdings has raised A$5 million through a placement to advance commercial gas production at its Red Lake field, with a follow-up Share Purchase Plan aiming to raise an additional A$2.1 million.

Clarity Pharmaceuticals has inked a pivotal supply agreement with Nusano to ensure a steady source of copper-67, a critical isotope for its upcoming Phase III prostate cancer trial and future commercialisation plans.

Hazer Group has received a $4.58 million R&D tax incentive refund for FY25, reinforcing its financial position as it advances its methane pyrolysis technology towards commercialisation.

Provaris Energy has launched a Robotics Innovation Centre in Norway, marking a pivotal step in fabricating and testing advanced hydrogen and liquid CO2 storage tanks. The initiative aims to accelerate prototype completion and commercial scalability by early 2026.

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Skin Elements Limited has locked in $2.5 million through a two-tranche placement to accelerate the commercial rollout of its SE Formula biotechnology products, offering investors discounted shares and options.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Cobre Limited has secured Environmental Impact Assessment approval for its In-Situ Copper Recovery pilot plant in Botswana, marking a pivotal step towards project development.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.